BIO.News Newsletter

Major news to start the weekend: Moderna’s moving forward with Phase 2 of the clinical trial of its COVID-19 vaccine candidate.  In advance of Mother’s Day (Sunday May 10), we have an exclusive feature on how Merck is addressing maternal health needs in the midst of the COVID-19 pandemic, plus the latest on what you can expect to happen on Capitol Hill next week. Read in about 5 minutes (1100 words)—then call your mom to say thanks.

Today we have another must-listen episode of the I AM BIO Podcast about a fascinating company using animal biotech to save human lives. More on that, plus updates on more BIO members’ COVID-19 treatment breakthroughs and the latest news from Washington, in about 530 words, 3 and a half minutes.

What can we expect in terms of coronavirus treatments and vaccines—and when? BIO’s Jim Greenwood and Merck’s Julie Gerberding have some insight on these questions, and how the industry’s rising to a very big challenge. We’re also looking at why you shouldn’t get TOO excited about lower levels of carbon emissions, and who’s calling Congress “a highly efficient virus spreading machine,” in just under 900 words, about 4 minutes, 22 seconds.

Vir and Alnylam have chosen their top pick for a COVID-19 therapeutic candidate, and they’re getting ready to start clinical trials. This is yet another great example of the industry’s unprecedented level of collaboration. Today, we've got news on a new IP platform that will facilitate this kind of collaboration, as well as how biotech can help ensure the sustainability of the world’s food supply, pandemic or not, in 770 words, just under 4 minutes.

The Senate is back in Washington today, and we’re starting the week with a deeper dive into the good news from Gilead. But we’re also looking at the link between air pollution and COVID-19 deaths—and those who are still denying it. Here are 855 words, about 4 minutes, 15 seconds.

Happy Friday. In case you missed it, Gilead Chairman and CEO Daniel O’Day joined NBC’s Savanah Guthrie on TODAY to discuss the latest development with the company’s experimental treatment remdesivir. As Guthrie notes during the interview, “We are in the midst of a pandemic and humanity is literally depending on companies like yours.” Watch the segment here.We’re taking you into the weekend with a look at why it’s more important than ever to continue research into zoonotic diseases—and what it…

Happy Friday. In case you missed it, Gilead Chairman and CEO Daniel O’Day joined NBC’s Savanah Guthrie on TODAY to discuss the latest development with the company’s experimental treatment remdesivir. As Guthrie notes during the interview, “We are in the midst of a pandemic and humanity is literally depending on companies like yours.” Watch the segment here.We’re taking you into the weekend with a look at why it’s more important than ever to continue research into zoonotic diseases—and what it…

Just two more days until the weekend. Today, we have a new episode of the I AM BIO Podcast, featuring a company using breakthrough RNA technology that might be able to block and destroy the genome of the coronavirus. We’re also looking at how biotech could save your summer stone fruits. Here are just under 800 words, just under 4 minutes.

JUST IN: For those just getting out of bed, STAT News is reporting that COVID-19 patients are responding to Gilead’s remdesivir – a sign of hope on the horizon. We also have news from the Trump administration on the meat industry and essential workers—and why PPE is so important. And, we’re closing out World Immunization Awareness Week with some big news on a COVID-19 vaccine. Here are about 965 words, just under 5 minutes.

ICYMI: New SEC rules that went into effect yesterday will help small biotechs research the medicines we need for COVID-19 and many other diseases. There's also more news on one BIO member doing incredible research with animal biotech to help humans fight this pandemic. Here are around 800 words, 4 minutes.